COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, will sell its long-acting insulin Tresiba in Europe at a 60-70 percent premium over rival product Lantus from France's Sanofi.
Reported by Reuters 1 day ago.
↧